新闻稿

Illumina Completes Acquisition of GenoLogics

SAN DIEGO--(BUSINESS WIRE)--Sep. 1, 2015-- Illumina, Inc. (NASDAQ: ILMN) today announced it has completed the acquisition of GenoLogics Life Science Software Inc., a developer of industry leading laboratory information management systems (LIMS) for life sciences organizations.

"We look forward to working with the talented team at GenoLogics and to further integrate their life science software as part of the overall Illumina informatics solution," said Francis deSouza, President of Illumina. “Adopted by more than 120 genomic labs worldwide, GenoLogics’s Clarity LIMS software strengthens our industry leading portfolio of genetic analysis solutions.”

The completion of the acquisition demonstrates Illumina’s commitment to drive the adoption of sequencing in new markets and improve the genomic workflow. GenoLogics’ Clarity LIMS™ software enables lab efficiencies and improved sample throughput with increased accuracy, fast turnaround, sample traceability, and preconfigured instrument integrations.

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Eric Endicott, 858-882-6822
pr@illumina.com

近期文章

因美纳员工如何推动医疗保健向精准医学迈进
因美纳员工如何推动医疗保健向精准医学迈进
多组学助力区分疑难卵巢癌病例中的良性和恶性肿瘤
多组学助力区分疑难卵巢癌病例中的良性和恶性肿瘤
多组学技术赋能青年科研力量,加速科研源头创新与转化
多组学技术赋能青年科研力量,加速科研源头创新与转化